BCYC — Bicycle Therapeutics Share Price
- $1.09bn
- $589.80m
- $26.98m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.93 | ||
Price to Tang. Book | 2.93 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 40.24 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -36.12% | ||
Return on Equity | -56.31% | ||
Operating Margin | -704.13% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 13.8 | 10.39 | 11.7 | 14.46 | 26.98 | 27.48 | 23.68 | 30.47% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 27th, 2017
- Public Since
- May 23rd, 2019
- No. of Shareholders
- 45
- No. of Employees
- 284
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 42,586,185
- Address
- Babraham Hall, CAMBRIDGE, CB21 6GS
- Web
- https://www.bicycletherapeutics.com/
- Phone
- +44 1223261503
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for BCYC
Bicycle Therapeutics PLC Annual Shareholders Meeting
Q2 2024 Bicycle Therapeutics PLC Earnings Release
Similar to BCYC
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 18:04 UTC, shares in Bicycle Therapeutics are trading at $25.49. This share price information is delayed by 15 minutes.
Shares in Bicycle Therapeutics last closed at $25.49 and the price had moved by +25.26% over the past 365 days. In terms of relative price strength the Bicycle Therapeutics share price has underperformed the S&P500 Index by -4.97% over the past year.
The overall consensus recommendation for Bicycle Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Bicycle Therapeutics does not currently pay a dividend.
Bicycle Therapeutics does not currently pay a dividend.
Bicycle Therapeutics does not currently pay a dividend.
To buy shares in Bicycle Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $25.49, shares in Bicycle Therapeutics had a market capitalisation of $1.09bn.
Here are the trading details for Bicycle Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BCYC
Based on an overall assessment of its quality, value and momentum Bicycle Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Bicycle Therapeutics is $43.20. That is 69.48% above the last closing price of $25.49.
Analysts covering Bicycle Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$5.19 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bicycle Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +5.14%.
As of the last closing price of $25.49, shares in Bicycle Therapeutics were trading +23.69% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bicycle Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $25.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Bicycle Therapeutics' directors